Lithium in the long-term treatment of bipolar disorders

European Archives of Psychiatry and Clinical Neuroscience

Volumn 253, Issue 3, 2003, Pages 120-125

  Kleindienst, Nikolaus ^a   Greil, W ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Psychiatric Private Clinic Sanatorium Kilchberg   (Switzerland)

Author keywords

Bipolar disorder; Effectiveness; Efficacy; Lithium; Maintenance treatment; Mood stabilizer; Review; Withdrawal symptoms

Indexed keywords

LITHIUM; TRANQUILIZER;

BIPOLAR DISORDER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INFANTILE HYPOTONIA; LONG TERM CARE; NEPHROGENIC DIABETES INSIPIDUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SUICIDAL BEHAVIOR; TERATOGENICITY; TREATMENT OUTCOME; MOOD DISORDER; RECURRENT DISEASE; WITHDRAWAL SYNDROME;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; LITHIUM; LONG-TERM CARE; MOOD DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0041328462     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-003-0429-2     Document Type: Review

References (75)

1. Akiskal HS, Bourgeois ML, Angst J, Post R, Möller HJ, Hirschfeld R (2000) Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 59 (Suppl 1):S5-S30
2. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996) Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 153:592-606
3. American Psychiatric Association (1994) Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 151 (Suppl):1-36
4. Angst J (1998) The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 50:143-151
5. Baastrup PC, Schou M (1967) Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16:162-172
6. Baastrup, PC, Poulsen JC, Schou M, Thomsen K, Amdisen A (1970) Prophylactic lithium: Double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 7668:326-330
7. Baldessarini RJ, Tondo L, Floris G, Rudas N (1997) Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 154:551-553
8. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ (1999) Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 60:9-21
9. Bowden CL, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty F, Hirschfeld RM, Gyulai L (1997) Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 33:693-699
10. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JC, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481-489
11. Bowden CL (2002) Pharmacological treatment of bipolar disorder: a review. In: Maj M, Akiskal HA, Lopez-Ibor JJ, Sartorius N (eds) Bipolar Disorder. Wiley. New York, pp 192-221
12. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392-400
13. Calabrese JR, Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434
14. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (2000) A double-blind, placebo -controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 61:841-850
15. Calabrese JR, Bowden C, DeVeaugh-Geiss J, Earl N, Gyulai L, Sachs G, M, Montgomery P (2001) Lamotrigine demonstrates long-term mood stabilization in recently manic patients. Presented at the American Psychiatric Association Annual Meeting, New Orleans, LA
16. Calabrese JR, Rapport DJ, Shelton MD. Pursuit of the Ideal Mood Stabilizer (2002) Time to give up and move to combination trials. In: Maj M, Akiskal HA, Lopez-Ibor JJ, Sartorius N (eds) Bipolar Disorder. Wiley. New York, pp 222-224
17. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML (1994) A reevaluation of risk of in utero exposure to lithium. J Am Med Assoc 271:146-150
18. Coppen A, Ghose K, Rao R, Bailey J, Peet M (1978) Mianserin and lithium in the prophylaxis of depression. Br J Psychiatry 133:206-210
19. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller MB (1997) Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychological Medicine 27:281-289
20. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T (1998) Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 155:895-898
21. Cundall RL, Brooks PW, Murray LG (1972) A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 3:308-311
22. Dickson WE, Kendell RE (1986) Does maintenance lithium therapy prevent recurrences of mania under ordinary clinical conditions? Psychol Med 16:521-530
23. Double DB (1996) Lithium revisited. Br J Psychiatry 168:381-382
24. Dunner DL, Stallone F, Fieve RR (1976) Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 33:117-120
25. Freeman MP, Stoll AL (1998) Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 155:12-21
26. Gershon S, Soares JC (1997) Current therapeutic profile of lithium. Arch Gen Psychiatry 54:16-20
27. Greil W, Broucek B, Klein HE, Engel-Sittenfeld P (1982) Discontinuation of lithium maintenance therapy: reversibility of clinical, psychological and neuroendocrinological changes. In: Emrich HR, Aldenhoff JB, Lux HD (eds) Basic mechanisms in the action of lithium. Excerpta Medica. Amsterdam, Oxford, Princeton, pp 235-248
28. Greil W, Ludwig-Mayerhofer W, Erazo E, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T (1996) Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40:179-190
29. Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders; a randomised study. J Affect Disord 43:151-161
30. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B (1998) Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18:455-460
31. Greil W, Kleindienst N (1999) The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 14:277-281
32. Greil W, Kleindienst N (2003) Concepts in the Treatment of Bipolar Disorder. Acta Psychiat Scand (in press)
33. Guscott R, Taylor L (1994) Lithium prophylaxis in recurrent affective illness. Br J Psychiatry 164:741-746
34. Harrow M, Goldberg JF, Grossman LS, Meltzer HY (1990) Outcome in manic disorders. A naturalistic follow-up study. Arch Gen Psychiatry 47:665-671
35. Johnson G (1998) Lithium; early development, toxicity, and renal function. Neuropsychopharmacol 19:200-205
36. Juckel G, Hegerl U, Mavrogiorgou P, Gallinat J, Mager T, Tigges P, Dresel S, Schröter A, Stotz G, Meller I, Greil W, Möller HJ (2000) Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. J Clin Psychiatry 61:585-593
37. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 39:1065-1069
38. nd ed. Springer. Berlin, Heidelberg, New-York, pp 435-445
39. Keck PE Jr, McElroy SL, Strakowski SM (1998) Anticonvulsants and antipsychotics in the treatment of bipolar disorder. Journal of Clinical Psychiatry 59 (Suppl. 69):74-81
40. Klein HE, Broucek B, Greil W (1981) Lithium withdrawal triggers psychotic states. Br J Psychiatry 139:255-256
41. Kleindienst N, Greil W, Rüger B, Möller HJ (1999) The prophylactic efficacy of lithium; transient or persistent? Eur Arch Psychiatry Clin Neurosci 249:144-149
42. Kleindienst N, Greil W (2002) Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychol Med 32:493-501
43. Levine J, Chengappa KN, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ (2000) Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar-Disord 2:120-130
44. Maj M, Starace F, Nolfe G, Kemali D (1986) Minimum plasma lithium levels required for effective prophylaxis in DSM III hipolar disorder: a prospective study. Pharmacopsychiatry 19:420-423
45. Maj M, Pirozzi R, Kemali D (1989) Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacol 98:535-538
46. Maj M, Pirozzi R, Magliano L (1995) Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry 152:1810-1811
47. Maj M, Pirozzi R, Magliano L, Bartoli L (1998) Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 155:30-35
48. Maj M (2000) The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disorders 2:93-101
49. Mander AJ (1989) Diagnosis change,lithium use and admissions for mania in Edinburgh. Acta Psychiatr Scand 80:434-436
50. Marini JL, Sheard MH, Bridges CI, Wagner E (1976) An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. Acta Psychiatr Scand 53:343-354
51. Markar HR, Mander AJ (1989) Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 155:496-500
52. McElroy SL, Keck PE, Pope HG (1987) Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 7:16-24
53. McIntyre RS, Mancini DA, Parikh S, Kennedy SH (2001) Lithium revisited. Can J Psychiatry 46:322-327
54. Melia PI (1970) Prophylactic lithium: a double-blind trial in recurrent affective disorders. Br J Psychiatry. 116:621-624
55. Moncrieff J (1995) Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 167:569-573
56. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe S (1981) A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacol 73:95-96
57. Oxtoby A, Jones A, Robinson M (1989) Is your "double-blind" design truly double-blind? Br J Psychiatry 155:700-701
58. Persson G (1972) Lithium prophylaxis in affective disorders. An open trial with matched controls. Acta Psychitr Scand 90:295-297
59. Pies R (2002) Have we undersold lithium for bipolar disorder? J Clin Psychopharmacol 22:445-449
60. Post RM, Leverich GS, Altshuler L, Mikalauskas K (1992) Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 149:1727-1729
61. Post RM, Leverich GS, Pazzaglia PJ, Mikalauskas K, Denicoff K (1993) Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch NJ, Padgham C, Hughes MAP-Studie (eds) Lithium in Medicine and Biology. Marius Press. Huddersfield (UK), pp 71-84
62. Prien RF, Caffey EM Jr, Klett J (1973) Prophylactic efficacy of lithium carbonate in manic depressive illness. Arch Gen Psychiatry 28:337-341
63. Sarfati Y, Spadone C, Vanelle JM, Loo H (1996) Inhibiteurs calciques et lithium dans le traitement prophylactique de la maladie maniaco-dé pressive. L'Encéphale 22:149-153
64. Schou M, Thomsen K, Baastrup PC (1970) Studies on the course of recurrent endogenous affective disorders. Int Pharmacopsychiatry 5:100-106
65. Schou M (1998) Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31:210-215
66. Schumann C, Lenz G, Berghöfer A, Müller-Oerlinghausen B (1999). Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 89:247-257
67. Shaw E (1986) Lithium Noncompliance. Psychiatr Ann 16:583-587
68. Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB (1995) Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 56:5-13
69. Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein S, Katz S, Geenens D, Swinson RP, Goethe JW, McGlashan T (1993) Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry 150:1668-1673
70. Suppes T, Baldessarini RJ, Faedda GL, Tohen M (1991) Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 48:1082-1088
71. Tohen M, Zarate CA Jr. (1998) Antipsychotic agents and bipolar disorder. J Clin Psychiatry 59 (Suppl. 1):38-48
72. Tohen M, Marnerros A, Bowden C, Greil W, Koukopoulos A, Belmaker H, Calabrese J, Yatham LN, Jacobs T, Baker RW, Williamson D, Evns AR, Dossenbach M, Cassano G (2002) Olanzapine versus Lithium in Relapse Prevention in Bipolar Disorder: A Randomized Double-blind Controlled 12-month Clinical Trial. Unpublished poster presented at the Third European Stanley Foundation Conference on Bipolar Disorder, Freiburg (FRG)
73. Tondo L, Baldessarini RJ, Floris G, Rudas N (1997) Effectiveness of restarting lithium treatment after its discontinuation in hipolar I and bipolar II disorders. Am J Psychiatry 154:548-550
74. Watkins SE, Callender K, Thomas DR, Tidmarsh SF, Shaw DM (1987) The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 150:180-182
75. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO (1995) Is clozapine a mood stabilizer? J Clin Psychiatry 56:108-112